Prostaglandins and Proinflammatory Cytokines

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 115-128

  Raisz, Lawrence G ^a,b   Lorenzo, Joseph A ^b  

^a Musculoskeletal Institute   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955752066     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50008-X     Document Type: Chapter

References (216)

1. Pilbeam C.C., Harrison J.R., Raisz L.G. Prostaglandins and bone metabolism. Principles of Bone Biology 2002, 979-994. Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
2. Bordin L., Priante G., Musacchio E., Giunco S., Tibaldi E., Clari G., Baggio B. Arachidonic acid-induced IL-6 expression is mediated by PKC alpha activation in osteoblastic cells. Biochemistry 2003, 42:4485-4491.
3. Traianedes K., Dallas M.R., Garrett I.R., Mundy G.R., Bonewald L.F. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 1998, 139:3178-3184.
4. Pilbeam C.C., Raisz L.G., Voznesensky O., Alander C.B., Delman B.N., Kawaguchi H. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J. Bone Miner. Res. 1995, 10:406-414.
5. Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., Ito A. An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 2003, 197:1303-1310.
6. Simon A.M., Manigrasso M.B., O'Connor J.P. Cyclooxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 2002, 17:963-976.
7. Bakker A.D., Klein-Nulend J., Burger E.H. Mechanotransduction in bone cells proceeds via activation of COX-2, but not COX-1. Biochem. Biophys. Res. Commun. 2003, 305:677-683.
8. Zhang X., Morham S.G., Langenbach R., Young D.A., Xing L., Boyce B.F., Puzas E.J., Rosier R.N., O'Keefe R.J., Schwarz E.M. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J. Bone Miner. Res. 2001, 16:660-670.
9. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 2002, 109:1405-1415.
10. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., Pilbeam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 2000, 105:823-832.
11. Chikazu D., Li X., Kawaguchi H., Sakuma Y., Voznesensky O.S., Adams D.J., Xu M., Hoshio K., Katavic V., Herschman H.R., Raisz L.G., Pilbeam C.C. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res. 2002, 17:1430-1440.
12. Choudbary S., Wadhwa S., Raisz L.G., Alander C., Pilbeam C.C. Extracellular calcium is a potent inducer of cyclo-oxygenase-2 in murine osteoblasts through an ERK signaling pathway. J. Bone Miner. Res. 2003, 18:1813-1824.
13. Krieger N.S., Parker W.R., Alexander K.M., Bushinsky D.A. Prostaglandins regulate acid-induced cell-mediated bone resorption. Am. J. Physiol. Renal Physiol. 2000, 279:F1077-F1082.
14. Bushinsky D.A., Parker W.R., Alexander K.M., Krieger N.S. Metabolic, but not respiratory, acidosis increases bone PGE(2) levels and calcium release. Am. J. Physiol. Renal Physiol. 2001, 281:1058-1066.
15. 2 directly inhibits bone-resorbing activity of isolated mature osteoclast mainly through the EP4 receptor. Calcif. Tissue Int. 2000, 67:85-92.
16. Romano C.L., Duci D., Romano D., Mazza M., Meani E. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J. Arthroplasty 2004, 19:14-18.
17. Saegusa M., Murakami M., Nakatani Y., Yamakawa K., Katagiri M., Matsuda K., Nakamura K., Kudo I., Kawaguchi H. Contribution of membrane-associated prostaglandin E2 synthase to bone resorption. J. Cell Physiol. 2003, 197:348-356.
18. Sakuma Y., Li Z., Pilbeam C.C., Alander C.B., Chikazu D., Kawaguchi H., Raisz L.G. Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E(2) and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone 2004, 34:827-834.
19. Fermor B., Jeffcoat D., Hennerbichler A., Pisetsky D.S., Weinberg J.B., Guilak F. The effects of cyclic mechanical strain and tumor necrosis factor alpha on the response of cells of the meniscus. Osteoarthritis Cartilage 2004, 12:956-962.
20. Huh Y.H., Kim S.H., Kim S.J., Chun J.S. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J. Biol. Chem. 2003, 278:9691-9697.
21. Thomas B., Thirion S., Humbert L., Tan L., Goldring M.B., Bereziat G., Berenbaum F. Differentiation regulates interleukin-1beta-induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. Biochem. J. 2002, 362:367-373.
22. LeGrand A., Fermor B., Fink C., Pisetsky D.S., Weinberg J.B., Vail T.P., Guilak F. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis. Rheum. 2001, 44:2078-2083.
23. Chow J.W., Fox S.W., Lean J.M., Chambers T.J. Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner. Res. 1998, 13:1039-1044.
24. Klein-Nulend J., Burger E.H., Semeins C.M., Raisz L.G., Pilbeam C.C. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner. Res. 1997, 12:45-51.
25. Forwood M.R. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 1996, 11:1688-1693.
26. Li J., Burr D.B., Turner C.H. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading. Calcif. Tissue. Int. 2002, 70:320-329.
27. Wadhwa S., Godwin S.L., Peterson D.R., Epstein M.A., Raisz L.G., Pilbeam C.C. Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway. J. Bone Miner. Res. 2002, 17:266-274.
28. Cherian P.P., Cheng B., Gu S., Sprague E., Bonewald L.F., Jiang J.X. Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J. Biol. Chem. 2003, 278:43146-43156.
29. Jiang J.X., Cheng B. Mechanical stimulation of gap junctions in bone osteocytes is mediated by prostaglandin E2. Cell Commun. Adhes. 2001, 8:283-288.
30. Saunders M.M., You J., Zhou Z., Li Z., Yellowley C.E., Kunze E.L., Jacobs C.R., Donahue H.J. Fluid flow-induced prostaglandin E2 response of osteoblastic ROS 17/2.8 cells is gap junction-mediated and independent of cytosolic calcium. Bone 2003, 32:350-356.
31. 2 induces expression of receptor activator of nuclear factor-kappaB ligand/osteoprotegrin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 2000, 15:1321-1329.
32. 2 in prostaglandin E receptor EP4-knockout mice. J. Biol. Chem. 2000, 275:19819-19823.
33. Sakuma Y., Tanaka K., Suda M., Komatsu Y., Yasoda A., Miura M., Ozasa A., Narumiya S., Sugimoto Y., Ichikawa A., Ushikubi F., Nakao K. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect. Immun. 2000, 68:6819-6825.
34. Sakuma Y., Tanaka K., Suda M., Yasoda A., Natsui K., Tanaka I., Ushikubi F., Narumiya S., Segi E., Sugimoto Y., Ichikawa A., Nakao K. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 2000, 15:218-227.
35. Tomita M., Li X., Okada Y., Woodiel F.N., Young R.N., Pilbeam C.C., Raisz L.G. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 2002, 30:159-163.
36. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000, 141:2054-2061.
37. Raisz L.G., Woodiel F.N. Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures. Prostaglandins Other Lipid Mediat. 2003, 71:287-292.
38. Brandstrom H., Jonsson K.B., Ohlsson C., Vidal O., Ljunghall S., Ljunggren O. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem. Biophys. Res. Commun. 1998, 247:338-341.
39. Suda K., Udagawa N., Sato N., Takami M., Itoh K., Woo J.T., Takahashi N., Nagai K. Suppression of osteoprotegerin expression by prostaglandin E(2) is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 2004, 172:2504-2510.
40. Li X., Pilbeam C.C., Pan L., Breyer R.M., Raisz L.G. Effects of prostaglandin E(2) on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 2002, 30:567-573.
41. 2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999, 140:1927-1935.
42. Granchi D., Amato I., Battistelli L., Ciapetti G., Pagani S., Avnet S., Baldini N., Giunti A. Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. Biomaterials 2005, 26:2371-2379.
43. Sakuma Y., Tanaka K., Suda M., Yasoda A., Natsui K., Tanaka I., Ushikubi F., Narumiya S., Segi E., Sugimoto Y., Ichikawa A., Nakao K. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 2000, 15:218-227.
44. Cui L., Ma Y.F., Yao W., Zhou H., Setterberg R.B., Liang T.C., Jee W.S. Cancellous bone of aged rats maintains its capacity to respond vigorously to the anabolic effects of prostaglandin E2 by modeling-dependent bone gain. J. Bone Miner. Metab. 2001, 19:29-37.
45. Zhou H., Ma Y.F., Yao W., Cui L., Setterberg R., Liang C.T., Jee W.S. Lumbar vertebral cancellous bone is capable of responding to PGE2 treatment by stimulating both modeling and remodeling-dependent bone gain in aged male rats. Calcif. Tissue Int. 2001, 68:179-184.
46. Ho M.L., Chang J.K., Chuang L.Y., Hsu H.K., Wang G.J. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem. Pharmacol. 1999, 58:983-990.
47. Centrella M., Casinghino S., McCarthy T.L. Differential actions of prostaglandins in separate cell populations from fetal rat bone. Endocrinology 1994, 135:1611-1620.
48. Keila S., Kelner A., Weinreb M. Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. J. Endocrinol. 2001, 168:131-139.
49. 2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. J. Cell. Biochem. 1999, 73:36-48.
50. Conconi M.T., Tommasini M., Baiguera S., De Coppi P., Parnigotto P.P., Nussdorfer G.G. Effects of prostaglandins E1 and E2 on the growth and differentiation of osteoblast-like cells cultured in vitro. Int. J. Mol. Med. 2002, 10:451-456.
51. Fall P.M., Breault D.T., Raisz L.G. Inhibition of collagen synthesis by prostaglandins in the immortalized rat osteoblastic cell line Pyla: Structure-activity relations and signal transduction mechanisms. J. Bone Miner. Res. 1994, 9:1935-1943.
52. Li M., Ke H.Z., Qi H., Healy D.R., Li Y., Crawford D.T., Paralkar V.M., Owen T.A., Cameron K.O., Lefker B.A., Brown T.A., Thompson D.D. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stiuulates local bone formation and enhances fracture healing. J. Bone Miner. Res. 2003, 18:2033-2042.
53. Paralkar V.M., Borovecki F., Ke H.Z., Cameron K.O., Lefker B., Grasser W.A., Owen T.A., Li M., DaSilva-Jardine P., Zhou M., Dunn R.L., Dumont F., Korsmeyer R., Krasney P., Brown T.A., Plowchalk D., Vukicevic S., Thompson D.D. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Natl Acad. Sci. USA 2003, 100:6736-6740.
54. Machwate M., Harada S., Leu C.T., Seedor G., Labelle M., Gallant M., Hutchins S., Lachance N., Sawyer N., Slipetz D., Metters K.M., Rodan S.B., Young R., Rodan G.A. Prostaglandin receptor EP(4), mediates the bone anabolic effects of PGE(2). Mol. Pharmacol. 2001, 60:36-41.
55. Shamir D., Keila S., Weinreb M. A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone 2004, 34:157-162.
56. Yoshida K., Oida H., Kobayashi T., Maruyama T., Tanaka M., Katayama T., Yamaguchi K., Segi E., Tsuboyama T., Matsushita M., Ito K., Ito Y., Sugimoto Y., Ushikubi F., Ohuchida S., Kondo K., Nakamura T., Narumiya S. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc. Natl Acad. Sci. USA 2002, 99:4580-4585.
57. Soper D.L., Wang Y., De B., deLong M.A., Dirr M.J., Soehner M.E., Lundy M.W., Mieling G.E., Wos J.A. The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis. Adv. Exp. Med. Biol. 2002, 507:303-307.
58. 2 on bone formation in cultured fetal rat calvariae: Role of insulin-like growth factor-1. Endocrinology 1993, 133:1504-1510.
59. Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., Rodan S.B. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 1994, 93:2490-2496.
60. Arikawa T., Omura K., Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J. Cell. Physiol. 2004, 200:400-406.
61. Paralkar V.M., Grasser W.A., Mansolf A.L., Baumann A.P., Owen T.A., Smock S.L., Martinovic S., Borovecki F., Vukicevic S., Ke H.Z., Thompson D.D. Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). J. Cell Physiol. 2002, 190:207-217.
62. Sabbieti M.G., Marehetti L., Abreu C., Montero A., Hand A.R., Raisz L.G., Hurley M.M. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology 1999, 140:434-444.
63. Chikazu D., Katagiri M., Ogasawara T., Ogata N., Shimoaka T., Takato T., Nakamura K., Kawaguchi H. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J. Bone. Miner. Res. 2001, 16:2074-2081.
64. Samoto H., Shimizu E., Matsuda-Honjyo Y., Saito R., Nakao S., Yamazaki M., Furuyama S., Sugiya H., Sodek J., Ogata Y. Prostaglandin E2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. J. Biol. Chem. 2003, 278:28659-28667.
65. Goldring M.B., Berenbaum F., Buckwalter J. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin. Orthop. 2004, 427(Suppl):S37-S46.
66. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr. Opin. Rheumatol. 2003, 15:623-627.
67. Notoya K., Jovanovic D.V., Reboul P., Martel-Pelletier J., Mineau F., Pelletier J.P. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J. Immunol. 2000, 165:3402-3410.
68. Geng Y., Blanco F.J., Cornelisson M., Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 1995, 155:796-801.
69. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., Pandher K., Lapointe J.M., Saha S., Roach M.L., Carter D., Thomas N.A., Durtchi B.A., McNeish J.D., Hambor J.E., Jakobsson P.J., Carty T.J., Perez J.R., Audoly L.P. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl Acad. Sci. USA 2003, 100:9044-9049.
70. McCoy J.M., Wicks J.R., Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 2002, 110:651-658.
71. Li T.F., Zuscik M.J., Ionescu A.M., Zhang X., Rosier R.N., Schwarz E.M., Drissi H., O'Keefe R.J. PGE2 inhibits chondrocyte differentiation through PKA and PKC signaling. Exp. Cell. Res. 2004, 300:159-169.
72. Boileau C., Martel-Pelletier J., Jouzeau J.Y., Netter P., Moldowan F., Laufer S., Tries S., Pelletier J.P. Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxy genase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J. Rheumatol. 2002, 29:1446-1453.
73. DiBattista J.A., Dore S., Morin N., Abribat T. Prostaglandin E(2) up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: Role of calcium and protein kinase A and C. J. Cell. Biochem. 1996, 63:320-333.
74. Hardy M.M., Seibert K., Manning P.T., Currie M.G., Woemer B.M., Edwards D., Koki A., Tripp C.S. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis. Rheum. 2002, 46:1789-1803.
75. Miyamoto M., Ito H., Mukai S., Kobayashi T., Yamamoto H., Kobayashi M., Maruyama T., Akiyama H., Nakamura T. Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. Osteoarthritis Cartilage 2003, 11:644-652.
76. Abramson S.B. The role of COX-2 produced by cartilage in arthritis. Osteoarthritis Cartilage 1999, 7:380-381.
77. Raisz L.G. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999, 7:419-421.
78. Raisz L.G. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am. J. Med. 2001, 110:43-45.
79. Crevenna R., Quittan M., Hulsmann M., Wiesinger G.F., Keilani M.Y., Kainberger F., Leitha T., Fialka-Moser V., Pacher R. Hypertrophic osteoarthropathy caused by PGE1 in a patient with congestive heart failure during cardiac rehabilitation. Wien. Klin. Wochenschr. 2002, 114:115-118.
80. 2 release by weight-bearing mechanical loading. j. Clin. Invest. 1996, 98:2446-2449.
81. Morton D.J., Barrett-Connor E.L., Schneider D.L. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bemardo study. J. Bone Miner. Res. 1998, 13:1924-1931.
82. Carbone L.D., Tylavsky F.A., Cauley J.A., Harris T.B., Lang T.F., Bauer D.C., Barrow K.D., Kritchevsky S.B. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res. 2003, 18:1795-1802.
83. Head J.E., Bryant B.J., Grills B.L., Ebeling P.R. Effects of short-term use of ibuprofen or acetaminophen on bone resorption in healthy men: a double-blind, placebo-controlled pilot study. Bone 2001, 29:437-441.
84. Teilelbaum S.L. Bone resorption by osteoclast. Science 2000, 289:1504-1508.
85. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
86. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakani A., Tsuda E., Moringa T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 1998, 95:3597-3602.
87. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
88. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
89. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
90. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
91. Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999, 140:3552-3561.
92. Lee S.K., Kalinowski J., Jastrzebski S., Lorenzo J.A. 1,25 (OH)(2) Vitamin D(3)-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J. Immunol. 2002, 169:2374-2380.
93. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259.
94. Vidal O.N., Sjögren K., Eriksson B.I., Ljunggren ö., Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1? in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Com. 1998, 248:696-700.
95. Pixley F.J., Stanley E.R. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell. Biol. 2004, 14:628-638.
96. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L.D., Nisikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
97. Wiktor Jedrzejczak W., Bartocci A., Ferrante A., Ahmed Ansari A., Sell K.W., Pollard J.W., Stanley E.R. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl Acad. Sci. USA 1990, 87:4828-4832.
98. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., Miyata T., Anderson D.M., Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 1999, 190:1741-1754.
99. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T., Kelley M., Burgess T.L., Boyle W.J., Polverino A.J. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 2000, 157:435-448.
100. Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., Stanley E.R. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99:111-120.
101. Cella M., Buonsanti C., Strader C., Kondo T., Salmaggi A., Colonna M. Impaired differentiation of osteoclast in TREM-2-deficient individuals. J. Exp. Med. 2003, 198:645-651.
102. Kim N., Takami M., Rho J., Josien R., Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 2002, 195:201-209.
103. Colonna M. DAP12 signaling: from immune cells to bone modeling and brain myelination. J. Clin. Invest. 2003, 111:313-314.
104. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaji M., Sugahara A., Koito H., Ujike-Asai A., Nakamura A., Kanazawa K., Tan-Takeuchi K., Iwasaki K., Yokoyama W.M., Kudo A., Fujiwara M., Ason H., Takai T. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 2003, 111:323-332.
105. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., Iwata T., Ohnishi H., Matozaki T., Kodama T., Taniguchi T., Takayanagi H., Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
106. Humphrey M.B., Ogasawara K., Yao W., Spusta S.C., Daws M.R., Lane N.E., Lanier L.L., Nakamura M.C. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 2004, 19:224-234.
107. Mocsai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., Majumdar S., Lanier L.L., Lowell C.A., Nakamura M.C. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcR gamma) regulate development of functional osteoclast through the Syk tyrosine kinase. Proc. Natl Acad. Sci. USA 2004, 101:6158-6163.
108. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 1991, 77:1627-1652.
109. Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: Idenity with interleukin 1 beta. J. Immunol. 1985, 135:2562-2568.
110. Lorenzo J.A., Sousa S., Alander C., Raisz L.G., Dinarello C.A. Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology 1987, 121:1164-1170.
111. Min Y.K., Rao Y., Okada Y., Raisz L.G., Pilbeam C.C. Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J. Bone Mine. Res. 1998, 13:1066-1075.
112. 2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and-independent mechanism in rat osteoblasts in vitro. J. Biol. Chem. 1999, 274:1776-1782.
113. Boyce B.F., Aufdemorte T.B., Garrett R., Yates A.J.P., Mundy G.R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989, 125:1142.
114. Smith D.D., Gowen M., Mundy G.R. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 1987, 120:2494-2499.
115. Canalis E. Interleukin-1 has independent effects on deoxyribonucleic acid and collagen synthesis in cultures of rat calvariae. Endocrinology 1986, 118:74-81.
116. Stashenko P., Dewhirst F.E., Rooney M.L., Desjardins L.A., Heeley J.D. Interleukin-1 Beta is a potent inhibitor of bone formation in vitro. J. Bone Miner. Res. 1987, 2:559-565.
117. Gowen M., Wood D.D., Russell G.G. Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity. J. Clin. Invest. 1985, 75:1223-1229.
118. Lorenzo J.A., Sousa S.L., Van Den Brink-Webb S.E., Korn J.H. Production of both interleukin-1 ? and ? by newborn mouse calvaria cultures. J. Bone Miner. Res. 1990, 5:77-83.
119. Kawaguchi H., Pilbeam C.C., Vargas S.J., Morse E.E., Lorenzo J.A., Raisz L.G. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvaria. J. Clin. Invest. 1995, 96:539-548.
120. Miyaura C., Kusano K., Masuzawa T., Chaki O., Onoe Y., Aoyagi M., Sasaki T., Tamura T., Koishihara Y., Ohsugi Y., Suda T. Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 1995, 10:1365-1373.
121. Horowitz M.C., Philbrick W.M., Jilka R.L. IL-1 release from cultured calvarial cells is due to macrophages. J. Bone Miner. Res. (abstr) 1989, 4(S1):556.
122. Keeting P.E., Rifas L., Harris S.A., Colvard D.S., Spelsberg T.C., Peck W.A., Riggs B.L. Evidence for interleukin-1 beta production by cultured normal human osteoblast-like cells. J. Bone Miner. Res. 1991, 6:827-833.
123. O'Keefe R.J., Teot L.A., Singh D., Puzas J.E., Rosier R.N., Hicks D.G. Osteoclast constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study. Lab. Invest. 1997, 76:457-465.
124. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T.J., Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 2000, 191:275-286.
125. Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T., Hannum C.H., Thompson R.C. Primary structure and functional expression from complementary DNA of a human interlukin-1 receptor antagonist. Nature 1990, 343:341-346.
126. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., Armes L.G., Sommer A., Eisenberg S.P., Thompson R.C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340.
127. Arend W.P., Welgus H.G., Thompson C., Eisenberg S.P. Biological properties of recombinant human monocytederived interleukin 1 receptor antagonist. J. Clin. Invest. 1990, 85:1694-1697.
128. Seckinger P., Klein-Nulend J., Alander C., Thompson R.C., Dayer J-M., Raisz L.G. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J. Immunol. 1990, 145:4181-4184.
129. Pacifici R., Vannice J.L., Rifas L., Kimble R.B. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. 1993, 77:1135-1141.
130. Abrahamsen B., Shalhoub V., Larson E., Eriksen E.F., Beck-Nielsen H., Marks S.C. IL-1 beta and IL-1 RA gene expression in transiliac bone biopsies: correlation with bone loss and histomorphometry in healthy postmenopausal women. J. Bone Miner. Res. 1996, 11:S42. (Abstract).
131. Dinarello C.A. Blocking interleukin-1 in disease. Blood Purif. 1993, 11:118-127.
132. Sims J.E., Gayle M.A., Slack J.L., Alderson M.R., Bird T.A., Giri J.G., Colotta F., Re F., Mantovani A., Shanebeck K., Grabstein K.H., Dower S.K. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl Acad. Sci. USA 1993, 90:6155-6159.
133. Eder J. Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all?. Trends Pharmacol. Sci. 1997, 18:319-322.
134. Martin M.U., Falk W. The interleukin-1 receptor complex and interleukin-1 signal transduction. Eur. Cytokine Netw. 1997, 8:5-17.
135. Korherr C., Hofmeister R., Wesche H., Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur. J. Immunol. 1997, 27:262-267.
136. Wesche H., Korherr C., Kracht M., Falk W., Resch K., Martin M.U. The interleukin-1 receptor accessory protein (IL-IRAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J. Biol. Chem. 1997, 272:7727-7731.
137. Huang J., Gao X., Li S., Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc. Natl Acad. Sci. USA 1997, 94:12829-12832.
138. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J.G., Dower S.K., Sims J.E., Mantovani A. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472-475.
139. Burger D., Chicheportiche R., Giri J.G., Dayer J-M. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type 1 interleukin-1 soluble receptor. J. Clin. Invest. 1995, 96:38-41.
140. Kitazawa R., Kimble R.B., Vannice J.L., Kung V.T., Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 1994, 94:2397-2406.
141. Lorenzo J.A., Naprta A., Rao Y., Alander C., Glaccum M., Widmer M., Gronowicz G., Kalinowski J., Pilbeam C.C. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 1998, 139:3022-3025.
142. Fiore C.E., Falcidia E., Foti R., Motta M., Tamburino C. Differences in the time course of the effects of oophorectomy in women on parameters of bone metabolism and interleukin-1 levels in the circulation. Bone Miner. 1994, 20:79-85.
143. McKane W.R., Khosla S., Peterson J.M., Egan K., Riggs B.L. Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. J. Bone Miner. Res. 1994, 9:1313-1318.
144. Khosla S., Peterson J.M., Egan K., Jones J.D., Riggs B.L. Circulating cytokine levels in osteoporotic and normal women. J. Clin. Endocrinol. Metab. 1994, 79:707-711.
145. Pilbeam C., Rao Y., Alander C., Voznesensky O., Okada Y., Sims J.E., Raisz L., Lorenzo J. Downregulation of mRNA expression for the "Decoy" interleukin-1 receptor 2 by ovariectomy in mice. J. Bone Miner. Res. 1997, 12:S433. (Abstract).
146. Sunyer T., Lewis J., Collin-Osdoby P., Osdoby P. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Invest. 1999, 103:1409-1418.
147. Iwamoto M., Koike T., Nakashima K., Sato K., Kato Y. Interleukin 1: a regulator of chondrocyte proliferation. Immunol. Lett. 1989, 21:153-156.
148. Morales T.I., Hascall V.C. Effects of interleukin-1 and lipopolysaccharides on protein and carbohydrate metabolism in bovine articular cartilage organ cultures. Connect. Tissue Res. 1989, 19:255-275.
149. Grumbles R.M., Shao L., Jeffrey J.J., Howell D.S. Regulation of rat interstitial collagenase gene expression in growth cartilage and chondrocytes by vitamin D3, interleukin-1 beta, and okadaic acid. J. Cell. Biochem. 1996, 63:395-409.
150. Goldring M.B., Birkhead J., Sandell L.J., Kimura T., Krane S.M. Interleukin 1 suppresses expression of cartilagespecific types II and IX collagens and increases types I and III collagens in human chondrocytes. J. Clin. Invest. 1988, 82:2026-2037.
151. Kato Y., Nakashima K., Iwamoto M., Murakami H., Hiranuma H., Koike T., Suzuki F., Fuchihata H., Ikehara Y., Noshiro M. Effects of interleukin-1 on syntheses of alkaline phosphatase, type X collagen, and 1,25-dihydroxyvitamin D3 receptor, and matrix calcification in rabbit chondrocyte cultures. J. Clin. Invest. 1993, 92:2323-2330.
152. Horan J., Dean D.D., Kieswetter K., Schwartz Z., Boyan B.D. Evidence that interleukin-1, but not interleukin-6, affects costochondral chondrocyte proliferation, differentiation, and matrix synthesis through an autocrine pathway. J. Bone Miner. Res. 1996, 11:1119-1129.
153. Dean D.D., Schwartz Z., Muniz O.E., Arsenis C.H., Boyan B.D., Howell D.S. Interleukin-1 alpha and beta in growth plate cartilage are regulated by vitamin D metabolites in vivo. J. Bone Miner. Res. 1997, 12:1560-1569.
154. Vargas S.J., Naprta A., Glaccum M., Lee S.K., Kalinowski J., Lorenzo J.A. Interleukin-6 expression and histomorphometry of bones from mice deficient for receptors for interleukin-1 or tumor necrosis factor. J. Bone Miner. Res. 1996, 11:1736-1744.
155. Martensson K., Chrysis D., Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J. Bone Miner. Res. 2004, 19:1805-1812.
156. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986, 320:584-588.
157. Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell 1988, 54:141-142.
158. Beutler B., Cerami A. Cachectin: More than a tumor necrosis factor. N. Eng. J. Med. 1987, 316:379-385.
159. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
160. Paul N.L., Ruddle N.H. Lymphotoxin. Ann. Rev. Immunol. 1988, 6:407-438.
161. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
162. Tashjian A.H., Voelkel E.F., Lazzaro M., Goad D., Bosma T., Levine L. Tumor necrosis factor-alpha (Cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 1987, 120:2029-2036.
163. Pfeilschifter J., Chenu C., Bird A., Mundy G.R., Roodman G.D. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J. Bone Miner. Res. 1989, 4:113-118.
164. Gowen M., Chapman K., Littlewood A., Hughes D., Evans D., Russell R.G.G. Production of tumor necrosis factor by human osteoblasts is modulated by other cytokines, but not by osteotropic hormones. Endocrinology 1990, 126:1250-1255.
165. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclast. J. Biol. Chem. 2000, 275:4858-4864.
166. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., Boyle W.J. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000, 97:1566-1571.
167. Fiers W. Tumor necrosis factor. The Natural Immune System: Humoral Factors 1993, 65-119. IRL Press at Oxford University Press, Oxford. E. Sim (Ed.).
168. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., Althage A., Zinkemagel R., Steinmetz M., Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:798-802.
169. Pfeffer K., Matsuyama T., Kündig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Krönke M., Mak T.W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467.
170. Erickson S.L.de S.F., Kikley K., Carver-Moore K., Pitts-Meek S., Gillett N., Sheehan K.C., Schreiber R.D., Goeddel D.V., Moore M.W. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994, 372:560-563.
171. Roggia C., Tamone C., Cenci S., Pacifici R., Isaia G.C. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva. Med. 2004, 95:125-132.
172. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl Acad. Sci. USA 2001, 98:13960-13965.
173. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000, 106:1481-1488.
174. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986, 322:547-549.
175. Lefebvre V., Peeters-Joris C., Vaes G. Production of gelatin-degrading matrix metalloproteinases ('type IV collagenases') and inhibitors by articular chondrocytes during their dedifferentiation by serial subcultures and under stimulation by interleukin-1 and tumor necrosis factor ?. Biochim. Biophys. Acta. Mol. Cell. Res. 1991, 1094:8-18.
176. Shinmei M., Masuda K., Kikuchi T., Shimomura Y. Interleukin 1 tumor necrosis factor, and interleukin 6 as mediators of cartilage destruction. Semin. Arthritis Rheum. 1989, 18:27-32.
177. Enomoto M., Pan H.O., Kinoshita A., Yutani Y., Suzuki F., Takigawa M. Effects of tumor necrosis factor alpha on proliferation and expression of differentiated phenotypes in rabbit costal chondrocytes in culture. Calcif. Tissue Int. 1990, 47:145-151.
178. Hashimoto J., Yoshikawa H., Takaoka K., Shimizu N., Masuhara K., Tsuda T., Miyamoto S., Ono K. Inhibitory effects of tumor necrosis factor alpha on fracture healing in rats. Bone 1989, 10:453-457.
179. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). F.A.S.E.B. J. 1990, 4:2860-2867.
180. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol. Today 1990, 11:443-449.
181. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell 1994, 76:253-262.
182. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T., Kishimoto T., Suda T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl Acad. Sci. USA 1993, 90:11924-11928.
183. Al-Humidan A., Ralston S.H., Hughes D.E., Chapman K., Aarden L., Russell R.G.G., Gowen M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J. Bone Miner. Res. 1991, 6:3-8.
184. Lowik C.W., Van der P.G., Bloys H., Hoekman K., Bijvoet O.L., Aarden L.A., Papapoulos S.E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogeneis. Biochem. Biophys. Res. Commun. 1989, 162:1546-1552.
185. Linkhart T.A., Linkhart S.G., MacCharles D.C., Long D.L., Strong D.D. Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: regulation by interleukin-1. J. Bone Miner. Res. 1991, 6:1285-1294.
186. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 1990, 145:3297-3303.
187. Roodman G.D. Interleukin-6 an osteotropic factor?. J. Bone Miner. Res. 1992, 7:475-478.
188. Manolagas S.C., Jilka R.L. Mechanisms of disease: Bone marrow, cytokines, and bone remodeling-Emerginginsights into the pathophysiology of osteoporosis. N. Eng. J. Med. 1995, 332:305-311.
189. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 1990, 144:4226-4230.
190. Black K., Garrett I.R., Mundy G.R. Chinese hamster ovary cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor bearing nude mice. Endocrinology 1991, 128:2657-2659.
191. De La Mata J., Uy H.L., Guise T.A., Story B., Boyce B.F., Mundy G.R., Roodman G.D. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Invest. 1995, 95:2846-2852.
192. Roodman G.D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., Smith J.F., Singer F.R. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 1992, 89:46-52.
193. Roodman G.D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 2001, 19:3562-3571.
194. Yamamoto T., Ozono K., Kasayama S., Yoh K., Hiroshima K., Takagi M., Matsumoto S., Michigami T., Yamaoka K., Kishimoto T., Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996, 98:30-35.
195. Reddy S.V., Takahashi S., Dallas M., Williams R.E., Neckers L., Roodman G.D. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J. Bone Miner. Res. 1994, 9:753-757.
196. Devlin R.D., Bone H.G., Roodman G.D. Interleukin-6 a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J. Clin. Endocrinol. Metab. 1996, 81:1893-1897.
197. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., Manolagas S.C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257:88-91.
198. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G.A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. E.M.B.O. J. 1994, 13:1189-1196.
199. Saggese G., Federico G., Cinquanta L. In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta. Paediatr. Suppl. 1993, 82(Suppl 391):54-59.
200. Guerne P.A., Carson D.A., Lotz M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J. Immunol. 1990, 144:499-505.
201. Pincus S.H., Schooley W.R., DiNapoli A.M., Broder S. Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients. Blood 1981, 58:1175-1181.
202. Shingu M., Miyauchi S., Nagai Y., Yasutake C., Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br. J. Rheumatol. 1995, 34:101-106.
203. Lotz M., Vaughan J.H., Carson D.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988, 241:1218-1221.
204. Manolagas S.C., Bellido T., Jilka R.L. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: Roles of IL-6 and gp130. int. J. Immunopharm. 1995, 17:109-116.
205. Romas E., Udagawa N., Zhou H., Tamura T., Saito M., Taga T., Hilton D.J., Suda T., Ng K.W., Martin T.J. The role of gp130-mediated signals in osteoclast development: Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 1996, 183:2581-2591.
206. Bellido T., Stahl N., Farruggella T.J., Borba V., Yancopoulos G.D., Manolagas S.C. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostain M, and ciliary neurotrophic factor in bone marrow stromal osteoblastic cells. J. Clin. Invest. 1996, 97:431-437.
207. Marusic A., Kalinowski J.F., Jastrzebski S., Lorenzo J.A. Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells. J. Bone Miner. Res. 1993, 8:617-624.
208. Greenfield E.M., Horowitz M.C., Lavish S.A. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem. 1996, 271:10984-10989.
209. Ishimi Y., Abe E., Jin C.H., Miyaura C., Hong M.H., Oshida M., Kurosawa H., Yamaguchi Y., Tomida M., Hozumi M., Suda T. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): Regulation of its production and possible roles in bone metabolism. J. Cell. Physiol. 1992, 152:71-78.
210. Reid I.R., Lowe C., Cornish J., Skinner S.J., Hilton D.J., Willson T.A., Gearing D.P., Martin D.J. Leukemia inhibitory factor: a novel bone-active cytokine. Endocrinology 1990, 126:1416-1420.
211. Lorenzo J.A., Sousa S.L., Leahy C.L. Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures. Cytokine 1990, 2:266-271.
212. Van Beek E., Van der Wee-Pals L., van de Ruit M., Nijweide P., Papapoulos S., Lowik C. Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture. J. Bone Miner. Res. 1993, 8:191-198.
213. Palmqvist P., Persson E., Conaway H.H., Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappaB ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvariae. J. Immunol. 2002, 169:3353-3362.
214. Ware C.B., Horowitz M.C., Renshaw B.R., Hunt J.S., Liggitt D., Koblar S.A., Gliniak B.C., McKenna H.J., Papayannopoulou T., Thoma B., Cheng L., Donovan P.J., Peschon J.J., Bartlett P.F., Willis C.R., Wright B.D., Carpenter M.K., Davison B.L., Gearing D.P. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 1995, 121:1283-1299.
215. Kawasaki K., Gao Y.H., Yokose S., Kaji Y., Nakamura T., Suda T., Yoshida K., Taga T., Kishimoto T., Kataoka H., Yuasa T., Norimatsu H., Yamaguchi A. Osteoclast are present in gp130-deficient mice. Endocrinology 1997, 138:4959-4965.
216. Sims N.A., Jenkins B.J., Quinn J.M., Nakamura A., Glatt M., Gillespie M.T., Ernst M., Martin T.J. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J. Clin. Invest. 2004, 113:379-389.